Martin P, Bartlett NL, Blum KA, et al. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
| Autor: | Nancy L. Bartlett, Peter Martin, Kristie A. Blum |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Maximum Tolerated Dose Pyridines Clinical Trials and Observations Immunology Lymphoma Mantle-Cell Palbociclib Biochemistry Piperazines chemistry.chemical_compound Piperidines Phase (matter) Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Aged 80 and over Chemistry Adenine Cell Biology Hematology Middle Aged Prognosis medicine.disease Survival Rate Pyrimidines Ibrutinib Cancer research Pyrazoles Female Mantle cell lymphoma Erratum Neoplasm Recurrence Local Previously treated Follow-Up Studies |
| Zdroj: | Blood. 134(11) |
| ISSN: | 1528-0020 |
| Popis: | Single-agent ibrutinib is active in patients with previously treated mantle cell lymphoma (MCL); however, nearly half of all patients experience treatment failure during the first year. We previously demonstrated that prolonged early G1 cell cycle arrest induced by the oral, specific CDK4/6 inhibitor palbociclib can overcome ibrutinib resistance in primary human MCL cells and MCL cell lines expressing wild-type Bruton's tyrosine kinase (BTK). Therefore, we conducted a phase 1 trial to evaluate the dosing, safety, and preliminary activity of palbociclib plus ibrutinib in patients with previously treated mantle cell lymphoma. From August 2014 to June 2016, a total of 27 patients (21 men, 6 women) were enrolled. The maximum tolerated doses were ibrutinib 560 mg daily plus palbociclib 100 mg on days 1 to 21 of each 28-day cycle. The dose-limiting toxicity was grade 3 rash. The most common grade 3 to 4 toxicities included neutropenia (41%), thrombocytopenia (30%), hypertension (15%), febrile neutropenia (15%), and lung infection (11%). The overall and complete response rates were 67% and 37%, and with a median follow-up of 25.6 months, the 2-year progression-free survival was 59.4% and the 2-year response duration was 69.8%. A phase 2 multicenter clinical trial to further characterize efficacy is now ongoing. The current trial was registered at www.clinicaltrials.gov as #NCT02159755. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|